Skip to content

Kyverna Therapeutics, Inc.

KYTX

CIK 0001994702

← back to feed
Revenue (TTM)
—
Q1 May 2026
Net Income (TTM)
−$163.23M
−26.5% YoY Q1 May 2026
EPS Diluted (TTM)
−$3.51
−9.3% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
−$123.5M
Q1 May 2026
Cash
$32.19M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
60.8M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings